Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

SOTIO Biotech

1/5/2022

April 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

by Jakub Jarolím, Business Intelligence Department

Market

Continued lack of financing and M&A drought led to NBI 10% during April

Through all market cap tiers struggled over first quarter 2022, large cap biopharmas performed the strongest, which could be a positive signal for the sector as large caps tend to recover first. The continued lack of financing activity and M&A drought led to NBI losing 10% during April.

Detail článku

Antibody-Drug Conjugates

April 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

Continued lack of financing and M&A drought led to NBI 10% during April

European Commision approved Padcev for locally advanced urothelial carcinoma

Nektar announced it will discontinue all bempeg programs and will focus on IL-15

Yescarta received FDA approval as first CAR-T for initial treatment of large B cell lymphoma

BeiGene’s tislelizumab meets primary endpoint in Phase 3

AZ entered deal with Harbour Biomed for Claudin18.2 bispecific for up to $350 million

Legal Notice